BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-03
180 industry Phase 2/3 trial readout(s) and 33 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-03 est. | P2 | Epitopoietic Research Corporation | NCT01903330 ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | Glioblastoma; Gliosarcoma | unknown | 84 |
| 2026-03 | P2 | Cumberland Pharmaceuticals CPIX | NCT02682511 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension | Scleroderma, Diffuse; Scleroderma, Systemic; Scleroderma, Limited; Sclerosis, Progressive Systemic; | active not recruiting | 34 |
| 2026-03 est. | P3 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | NCT04357522 Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers | Pneumonia, Pneumococcal | unknown | 1950 |
| 2026-03 est. | P1/P2 | PT. Prodia Stem Cell Indonesia | NCT05008588 Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct | Ischemic Stroke | active not recruiting | 15 |
| 2026-03 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05416749 A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors | Solid Tumors | suspended | 216 |
| 2026-03 est. | P2 | Kira Pharmacenticals (US), LLC. | NCT05504187 Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | withdrawn | |
| 2026-03 est. | P3 | Binhui Biopharmaceutical Co., Ltd. | NCT05868707 OH2 Injection in Melanoma | Melanoma | recruiting | 340 |
| 2026-03 est. | P1/P2 | Forward Pharmaceuticals Co., Ltd. FWRD | NCT06064812 A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer Stage IV; ER+/HER2- Breast C | recruiting | 99 |
| 2026-03 est. | P1/P2 | Hansoh BioMedical R&D Company | NCT06144723 Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. | Advanced Solid Tumor | not yet recruiting | 402 |
| 2026-03 est. | P1/P2 | Hinova Pharmaceuticals Inc. | NCT06155084 A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | Metastatic Castration-resistant Prostate Cancer | recruiting | 84 |
| 2026-03 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06198764 A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection | Mental Health Issue | unknown | 80 |
| 2026-03 est. | P2 | Alethia Biotherapeutics | NCT06225843 Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis | Metastatic Colorectal Cancer | recruiting | 17 |
| 2026-03 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06239298 A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor | Solid Tumor | unknown | 130 |
| 2026-03 est. | P2 | Spinogenix | NCT06442462 Study of SPG302 in Adults With Schizophrenia | Schizophrenia | active not recruiting | 32 |
| 2026-03 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06566586 A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma | B-cell Lymphoma | recruiting | 80 |
| 2026-03 est. | P2 | AmacaThera Inc. | NCT06709612 Postsurgical Analgesia After Hernia Repair | Hernia Repair; Hernia Inguinal; Hernia Surgery; Hernia, Inguinal/Surgery; Hernia, Inguinal | withdrawn | |
| 2026-03 est. | P2 | nephCentric | NCT06798675 Phase 2a Study for PK/PD of nC-001 | CHRONIC HYPONATREMIA | not yet recruiting | 24 |
| 2026-03 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06825494 Clinical Studies for the Treatment of Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 194 |
| 2026-03 est. | P3 | Chiesi Farmaceutici S.p.A. | NCT06917690 A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa | Epidermolysis Bullosa; Junctional Epidermolysis Bullosa; Epidermolysis Bullosa, Dystrophic; Epidermo | recruiting | 6 |
| 2026-03 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06918743 To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study | Psoriatic Subjects | not yet recruiting | 147 |
| 2026-03 est. | P3 | Xiamen Amoytop Biotech Co., Ltd. | NCT06927310 The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature | Idiopathic Short Stature | recruiting | 300 |
| 2026-03 est. | P2 | BiomX Ltd | NCT06998043 Study With Phage for CF Subjects With Pseudomonas Lung Infection | Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF) | recruiting | 63 |
| 2026-03 est. | P3 | Changchun BCHT Biotechnology Co. | NCT07133802 Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccinat | Prevention of Influenza | not yet recruiting | 6680 |
| 2026-03 est. | P3 | Aresus Pharma GmbH | NCT07137819 Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis | Actinic Keratosis of Face and Scalp | recruiting | 280 |
| 2026-03 est. | P3 | Mather's Pharm. Co., Ltd. | NCT07181148 A Study to Evaluate the Safety and Effectiveness of MSP01-T for Bowel Cleansing Before a Colonoscopy | Colonoscopy; Bowel Preparation | not yet recruiting | 214 |
| 2026-03 est. | P2 | Guangzhou Patronus Biotech Co., Ltd. | NCT07208461 A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older | Respiratory Syncytial Virus Infection Prevention | active not recruiting | 700 |
| 2026-03 est. | P1/P2 | Nasus Pharma NSRX | NCT07228325 Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis | Anaphylaxis; Allergy | enrolling by invitation | 50 |
| 2026-03 est. | P2 | Aspargo Labs, Inc | NCT07231185 Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction | Erectile Dysfunction | not yet recruiting | 200 |
| 2026-03 est. | P2 | Anhui Palo Alto Pharmaceuticals, Inc. | NCT07324707 Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma | Bronchial Asthma | recruiting | 30 |
| 2026-03 est. | P2 | Next Life Sciences | NCT07393334 Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive | Male Contraception; Semen Volume; Sperm Motility | recruiting | 10 |
| 2026-03-01 | P2 | CellSight Technologies, Inc. | NCT04260256 A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors | Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit | terminated | 9 |
| 2026-03-01 est. | P2 | Replimune, Inc. REPL | NCT05743270 Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Squamous Cell Carcinoma of Head and Neck; Locally Advanced Head and Neck Squamous Cell Carcinoma; Re | withdrawn | |
| 2026-03-01 est. | P2 | TRYP Therapeutics | NCT06206265 Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) | Irritable Bowel Syndrome | active not recruiting | 14 |
| 2026-03-01 est. | P1/P2 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT06223841 A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | Advanced Malignant Tumors | recruiting | 50 |
| 2026-03-01 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06281678 A Study of IBI363 in Subjects with Advanced Solid Malignancies | Melanoma; Non-small Cell Lung Cancer; Colorectal Cancer; Renal Cell Cancer | recruiting | 178 |
| 2026-03-01 est. | P1/P2 | Nuwacell Biotechnologies Co., Ltd. | NCT06825169 A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease | Interstitial Lung Disease (ILD) | not yet recruiting | 30 |
| 2026-03-01 est. | P2 | TNF Pharmaceuticals, Inc. | NCT06942182 Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures | Sarcopenia in Elderly; Frailty; Frailty/Sarcopenia; Frailty in Older Adults | not yet recruiting | 60 |
| 2026-03-01 est. | P1/P2 | U: The Mind Company | NCT07182058 Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms | PARKINSON DISEASE (Disorder) | recruiting | 30 |
| 2026-03-02 | P3 | Zeria Pharmaceutical | NCT04526119 A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia | Functional Dyspepsia | completed | 55 |
| 2026-03-02 | P3 | Sanofi SNY | NCT04910776 Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa | Glycogen Storage Disease Type II | active not recruiting | 17 |
| 2026-03-02 | P3 | AstraZeneca AZN | NCT04960709 Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer In | Muscle Invasive Bladder Cancer | active not recruiting | 712 |
| 2026-03-02 est. | P1/P2 | Gracell Biotechnologies (Shanghai) Co., Ltd. | NCT06235229 A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | recruiting | 110 |
| 2026-03-02 | P3 | Sanofi SNY | NCT06805513 Actual Use Trial of Tadalafil 5 mg | Erectile Dysfunction | completed | 2212 |
| 2026-03-03 | P2 | Incyte Corporation INCY | NCT02723994 A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | Leukemia | completed | 171 |
| 2026-03-03 | P3 | Akero Therapeutics, Inc | NCT06161571 A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis ( | NASH/MASH; NAFLD/MASLD | active not recruiting | 700 |
| 2026-03-03 | P2 | Genentech, Inc. | NCT06602453 A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE | Acute Kidney Injury | terminated | 67 |
| 2026-03-03 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06790862 A Trial of SHR0302Base in Patients With Vitiligo | Vitiligo | active not recruiting | 155 |
| 2026-03-04 | P3 | Eli Lilly and Company LLY | NCT03519945 A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) | Ulcerative Colitis | active not recruiting | 1058 |
| 2026-03-04 est. | P3 | AstraZeneca AZN | NCT05348577 Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) | Prostate Cancer | active not recruiting | 1035 |
| 2026-03-04 | P3 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05861128 Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS) | Ankylosing Spondylitis | completed | 207 |
| 2026-03-04 | P2 | Hoffmann-La Roche | NCT06128564 A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrop | Duchenne Muscular Dystrophy | active not recruiting | 13 |
| 2026-03-04 | P3 | Novo Nordisk A/S NVO | NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With | Type 2 Diabetes | completed | 1024 |
| 2026-03-04 | P2 | Gilead Sciences GILD | NCT06290934 Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 228 |
| 2026-03-04 | P3 | Viridian Therapeutics, Inc. VRDN | NCT06625398 An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) | Thyroid Eye Disease | active not recruiting | 204 |
| 2026-03-05 | P2 | AltruBio Inc. | NCT06109441 Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics | Ulcerative Colitis | active not recruiting | 50 |
| 2026-03-05 | P2/P3 | Merck Sharp & Dohme LLC MRK | NCT06295809 A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) | Carcinoma, Squamous Cell; Skin Neoplasms | terminated | 46 |
| 2026-03-05 | P2 | SkinJect, Inc. | NCT06608238 Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma. | Nodular Basal Cell Carcinoma | completed | 90 |
| 2026-03-06 | P1/P2 | Hemerion Therapeutics | NCT05736406 A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | Primary Glioblastoma | active not recruiting | 12 |
| 2026-03-06 | P1/P2 | Carrick Therapeutics Limited | NCT05963997 A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer | completed | 49 |
| 2026-03-06 | P3 | AstraZeneca AZN | NCT06040086 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1454 |
| 2026-03-06 | P2 | Elixiron Immunotherapeutics Inc. | NCT06745583 A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients | Mild, Moderate, or Severe Alzheimer's Disease | completed | 7 |
| 2026-03-07 | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06738979 A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects | Obesity | completed | 408 |
| 2026-03-09 | P1/P2 | Aprea Therapeutics APRE | NCT04905914 Study Of ATRN-119 In Patients With Advanced Solid Tumors | Advanced Solid Tumor | completed | 43 |
| 2026-03-09 | P2 | Biogen BIIB | NCT05348785 A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 | Parkinson Disease | completed | 650 |
| 2026-03-09 | P2 | Novo Nordisk A/S NVO | NCT05725902 Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease | Sickle Cell Disease | completed | 12 |
| 2026-03-09 | P2 | Shanghai Mabgeek Biotech.Co.Ltd | NCT07103174 A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis | Atopic Dermatitis (AD) | completed | 60 |
| 2026-03-09 | P2 | Suzhou Abogen Biosciences Co., Ltd. | NCT07285278 Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above | Varicella-zoster Virus | active not recruiting | 300 |
| 2026-03-10 | P3 | Amgen AMGN | NCT03937154 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | Chemotherapy-induced Thrombocytopenia | active not recruiting | 145 |
| 2026-03-10 | P2 | MapLight Therapeutics MPLT | NCT05081245 ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) | Autism Spectrum Disorder | completed | 168 |
| 2026-03-10 | P1/P2 | ALK-Abelló A/S | NCT05440643 Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy | Peanut Allergy | completed | 209 |
| 2026-03-10 | P3 | Incepta Pharmaceuticals Ltd | NCT06305416 A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema | Diabetic Macular Edema; Diabetic Retinopathy; Macular Edema; Macular Degeneration; Retinal Disease; | completed | 70 |
| 2026-03-10 | P3 | Samsung Bioepis Co., Ltd. | NCT06348199 A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell | Non-small Cell Lung Cancer Stage IV | active not recruiting | 555 |
| 2026-03-10 est. | P1/P2 | Bio-Thera Solutions | NCT06545617 A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer | Platinum-resistant Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | withdrawn | |
| 2026-03-11 | P3 | argenx ARGX | NCT04225156 A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | Primary Immune Thrombocytopenia | completed | 101 |
| 2026-03-11 | P2 | Biogen BIIB | NCT05399888 A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to | Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease Dementia | active not recruiting | 416 |
| 2026-03-11 | P3 | Alzheon Inc. | NCT06304883 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects | Early Alzheimer's Disease | terminated | 163 |
| 2026-03-11 | P2 | AbViro LLC | NCT06799741 A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection | DENV-3 Controlled Human Infection Model | completed | 85 |
| 2026-03-11 | P2 | EIP Pharma Inc | NCT06815965 A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | Dementia With Lewy Bodies (DLB) | completed | 26 |
| 2026-03-12 | P3 | Regeneron Pharmaceuticals REGN | NCT05352672 Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally | Melanoma | active not recruiting | 1546 |
| 2026-03-12 | P1/P2 | BioNTech SE BNTX | NCT05547464 Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers | Tuberculosis | active not recruiting | 497 |
| 2026-03-12 | P3 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05676242 A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis | Atopic Dermatitis | completed | 207 |
| 2026-03-12 | P2 | Merck Sharp & Dohme LLC MRK | NCT06036836 Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer | completed | 163 |
| 2026-03-12 | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06425159 A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures | Generalized Epilepsy | terminated | 27 |
| 2026-03-12 | P3 | Merck Sharp & Dohme LLC MRK | NCT06698042 A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | Lung Cancer; Non-Small Cell Lung Cancer | active not recruiting | 67 |
| 2026-03-13 | P2 | Synairgen Research Ltd. | NCT06999603 Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection | Viral Pneumonia | terminated | 11 |
| 2026-03-14 | P2 | Jemincare | NCT06949020 A Dose-finding Study of JMKX003142 in Treatment of Cardiac Edema | Cardiac Edema | completed | 160 |
| 2026-03-15 est. | P3 | Vera Therapeutics, Inc. VERA | NCT05609812 Atacicept in Subjects With Active Lupus Nephritis (COMPASS) | Lupus Nephritis (LN) | withdrawn | |
| 2026-03-15 | P1/P2 | Enlivex Therapeutics Ltd. ENLV | NCT06233474 Study of Intra-articular Allocetra in Knee Osteoarthritis | Osteoarthritis, Knee | completed | 134 |
| 2026-03-16 est. | P3 | AstraZeneca AZN | NCT03997123 Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC | Triple Negative Breast Neoplasms | active not recruiting | 923 |
| 2026-03-16 | P2 | Vir Biotechnology, Inc. VIR | NCT04856085 Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection | Hepatitis B, Chronic | completed | 244 |
| 2026-03-16 | P3 | Eli Lilly and Company LLY | NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardio | Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney | completed | 2749 |
| 2026-03-16 | P2 | Aptarion Biotech AG | NCT05962606 Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. | Community-acquired Pneumonia | completed | 150 |
| 2026-03-16 | P3 | Sandoz | NCT06159790 A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-sm | Metastatic NSCLC | completed | 218 |
| 2026-03-16 | P2/P3 | Gilead Sciences GILD | NCT06613685 Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated | HIV-1-infection | terminated | 73 |
| 2026-03-16 est. | P3 | Baxis Pharmaceuticals, Inc. | NCT06911424 Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis | Bacterial Conjunctivitis | recruiting | 400 |
| 2026-03-17 | P2 | Agios Pharmaceuticals, Inc. AGIO | NCT05490446 A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Myelodysplastic Syndromes | active not recruiting | 87 |
| 2026-03-17 | P2 | Cynata Therapeutics Limited | NCT05643638 A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD | Graft Versus Host Disease, Acute | terminated | 65 |
| 2026-03-17 | P3 | Incyte Corporation INCY | NCT06113471 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | NonSegmental Vitiligo | active not recruiting | 450 |
| 2026-03-17 | P2 | Celldex Therapeutics CLDX | NCT06366750 A Study of Barzolvolimab in Patients With Prurigo Nodularis | Prurigo Nodularis | active not recruiting | 140 |
| 2026-03-17 | P3 | BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | NCT06704581 A Study of BGM0504 Injection in Participants With Obesity or Overweight | Overweight or Obesity | completed | 652 |
| 2026-03-18 | P1/P2 | Avidity Biosciences, Inc. | NCT05747924 Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | FSHD; FSHD1; FSHD2; FMD; FMD2; Fascioscapulohumeral Muscular Dystrophy; Fascioscapulohumeral Muscula | completed | 90 |
| 2026-03-18 | P2 | Eisai Inc. | NCT06188559 A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breas | Breast Cancer | completed | 56 |
| 2026-03-18 | P2 | Biohaven Therapeutics Ltd. BHVN | NCT06423781 Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) | Major Depressive Disorder | completed | 233 |
| 2026-03-18 est. | P2 | Shanghai Bao Pharmaceuticals Co., Ltd. | NCT07025408 Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns | Burn; Burn Wounds - Partial Thickness (2nd Degree) | recruiting | 144 |
| 2026-03-19 | P1/P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer | Cervical Cancer | terminated | 214 |
| 2026-03-19 | P2/P3 | CSL Behring | NCT03805789 The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant | Acute-graft-versus-host Disease | terminated | 222 |
| 2026-03-19 | P2 | Novartis Pharmaceuticals NVS | NCT05268289 Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Lupus Nephritis | terminated | 81 |
| 2026-03-19 est. | P3 | Hoffmann-La Roche | NCT05494619 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) | Guillain-Barré Syndrome | withdrawn | |
| 2026-03-19 | P3 | Astellas Pharma Inc | NCT06206421 A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause | Hot Flashes | completed | 277 |
| 2026-03-19 est. | P3 | Gan & Lee Pharmaceuticals. | NCT06767761 A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin | Diabetes | active not recruiting | 580 |
| 2026-03-19 | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06780267 Clinical Study of HRS-2129 for Postoperative Analgesia in Orthopaedics | Postoperative Pain in Orthopaedics | completed | 199 |
| 2026-03-19 | P2 | Eli Lilly and Company LLY | NCT06817356 A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | Alcohol Use Disorder | completed | 308 |
| 2026-03-19 | P2 | Engrail Therapeutics INC | NCT07193563 A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder | Social Anxiety Disorder (SAD) | completed | 47 |
| 2026-03-20 | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT03485209 Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Exocrine Pancreatic Cancer; Carcinoma, Squamou | active not recruiting | 350 |
| 2026-03-20 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05814354 SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial | Breast Cancer | active not recruiting | 551 |
| 2026-03-20 | P2 | Bioxodes S.A. | NCT05970224 A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral | Intracerebral Hemorrhage | completed | 23 |
| 2026-03-20 | P3 | Arthrosi Therapeutics | NCT06439602 Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) | Gout; Arthritis, Gouty; Hyperuricemia; Gout Chronic | completed | 818 |
| 2026-03-21 | P2/P3 | REDNVIA Co., Ltd. | NCT05143177 A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) | Calcific Aortic Valve Disease | terminated | 486 |
| 2026-03-21 | P2 | Shanghai Minwei Biotechnology Co., Ltd | NCT07791654 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants W | Overweight , Obesity | completed | 120 |
| 2026-03-21 | P2 | Shanghai Minwei Biotechnology Co., Ltd | NCT07804810 Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity | Overweight , Obesity | completed | 120 |
| 2026-03-22 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06637254 A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma | Bronchial Asthma | unknown | 219 |
| 2026-03-23 | P2 | Caliway Biopharmaceuticals Co., Ltd. | NCT06303570 A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas | Dercum's Disease | completed | 19 |
| 2026-03-23 | P3 | LuciLab | NCT06748625 Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Prevention | Risk Behavior; Cognitive Decline | completed | 368 |
| 2026-03-23 | P2 | Corxel Pharmaceuticals | NCT07011797 A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants | Obesity | completed | 250 |
| 2026-03-24 | P3 | Abnoba Gmbh | NCT02106572 Therapeutic Instillation of Mistletoe | Superficial Bladder Cancer | terminated | 174 |
| 2026-03-24 | P1/P2 | BriaCell Therapeutics Corporation BCTX | NCT03328026 Combination Study of SV-BR-1-GM With Retifanlimab | Breast Cancer; Breast Neoplasm; Metastatic Breast Cancer; Breast Cancer Metastatic | completed | 36 |
| 2026-03-24 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06727058 Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | Influenza Immunization | completed | 276 |
| 2026-03-25 | P1/P2 | Kite, A Gilead Company | NCT02625480 Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B-Cell Non-Hodgkin | completed | 95 |
| 2026-03-25 | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT04136171 CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants Wi | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | completed | 1438 |
| 2026-03-25 | P3 | Novartis Pharmaceuticals NVS | NCT04926818 Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis | Multiple Sclerosis (MS) | active not recruiting | 129 |
| 2026-03-25 | P1/P2 | Genmab GMAB | NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial | Breast Cancer, Breast Neoplasms; Endometrial Cancer, Endometrial Neoplasm; Ovarian Cancer, Ovarian N | terminated | 179 |
| 2026-03-25 | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT05304767 An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | Schizophrenia | completed | 290 |
| 2026-03-25 | P3 | Novartis Pharmaceuticals NVS | NCT06267560 Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | completed | 422 |
| 2026-03-25 | P3 | Avadel | NCT06525077 Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ) | Idiopathic Hypersomnia | completed | 157 |
| 2026-03-25 | P1/P2 | EyeBiotech Ltd. | NCT06664502 A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-findin | Diabetic Macular Edema (DME); Neovascular Age-related Macular Degeneration (NVAMD); BRVO - Branch Re | completed | 38 |
| 2026-03-25 | P1/P2 | Capsida Biotherapeutics, Inc. | NCT06983158 A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy | Developmental and Epileptic Encephalopathy | terminated | 1 |
| 2026-03-25 | P2 | Oruka Therapeutics, Inc. ORKA | NCT07090330 ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | active not recruiting | 80 |
| 2026-03-26 | P1/P2 | Ascletis Pharma (China) Co., Limited | NCT06679959 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity | Chronic Weight Management | completed | 115 |
| 2026-03-26 | P3 | Gan & Lee Pharmaceuticals. | NCT06728124 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects | Obesity/Overweight | completed | 640 |
| 2026-03-26 | P2 | Janssen Research & Development, LLC | NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) | Dermatitis, Atopic | terminated | 256 |
| 2026-03-27 | P2 | Clementia Pharmaceuticals Inc. | NCT05039515 A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (F | Fibrodysplasia Ossificans Progressiva | terminated | 113 |
| 2026-03-27 | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT06003231 A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms | active not recruiting | 120 |
| 2026-03-27 | P2 | Regeneron Pharmaceuticals REGN | NCT06299111 A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Cathe | Venous Thromboembolism | completed | 195 |
| 2026-03-27 | P3 | ModernaTX, Inc. | NCT07117487 A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age | Respiratory Syncytial Virus | completed | 507 |
| 2026-03-28 est. | P3 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT06543966 Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting | Post-operative Nausea and Vomiting (PONV) | unknown | 486 |
| 2026-03-28 est. | P3 | Lunan Better Pharmaceutical Co., LTD. | NCT06879782 Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease | Dry Eye Disease (DED) | recruiting | 820 |
| 2026-03-29 | P3 | MAXVAX Biotechnology Limited Liability Company | NCT06447779 Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older | Herpes Zoster | active not recruiting | 25000 |
| 2026-03-30 est. | P2 | Apollomics Inc. APLM | NCT03175224 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Solid Tumors; Advanced Cancer; Renal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinom | recruiting | 497 |
| 2026-03-30 | P1/P2 | Takeda TAK | NCT04420884 A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | Solid Neoplasms | completed | 248 |
| 2026-03-30 est. | P1/P2 | Criterium, Inc. | NCT05230810 Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | HER2-positive Metastatic Breast Cancer | active not recruiting | 40 |
| 2026-03-30 | P3 | Incyte Corporation INCY | NCT05429268 Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma | active not recruiting | 82 |
| 2026-03-30 est. | P2 | Artcline GmbH | NCT05442710 Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy | Sepsis, Severe | recruiting | 142 |
| 2026-03-30 | P3 | AstraZeneca AZN | NCT05883644 Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) | Advanced Hepatocellular Carcinoma | active not recruiting | 111 |
| 2026-03-30 | P1/P2 | Agyany Pharma LTD | NCT06193421 High-Dose Ambroxol in GBA1-Related Parkinson | Parkinson Disease; GBA Gene Mutation | terminated | 46 |
| 2026-03-30 | P1/P2 | Genmab GMAB | NCT06685068 A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | terminated | 23 |
| 2026-03-30 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06771245 A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients | Mild-to-moderate Essential Hypertension | not yet recruiting | 606 |
| 2026-03-30 | P2 | PRG Science & Technology Co., Ltd. | NCT06775041 Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGP | Hutchinson-Gilford Progeria Syndrome | completed | 10 |
| 2026-03-30 | P3 | Vanda Pharmaceuticals VNDA | NCT06836557 Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis | Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis | completed | 17 |
| 2026-03-30 est. | P2 | Guangzhou JOYO Pharma Co., Ltd | NCT06895031 Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Solid Tumor; Pancreatic Ductal Adenocarcinoma (PDAC); Non-small Cell Lung Cancer (NSCLC); Colorectal | recruiting | 210 |
| 2026-03-30 | P3 | HAL Allergy | NCT06920771 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in | House Dust Mite Allergy; House Dust Mite Rhinitis | completed | 691 |
| 2026-03-30 est. | P2 | Guangzhou Novaken Pharm Co., Ltd. | NCT07156773 The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes | Parkinson Disease | recruiting | 84 |
| 2026-03-30 est. | P2 | Guangzhou Novaken Pharm Co., Ltd. | NCT07168720 The Study is Being Conducted to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Microneedles for Preoperative Sedation in Children | Preoperative Sedation | recruiting | 64 |
| 2026-03-31 | P3 | Optinose US Inc. | NCT03747458 OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps | Bilateral Nasal Polyposis | completed | 40 |
| 2026-03-31 | P3 | ADC Therapeutics S.A. ADCT | NCT04384484 Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | 440 |
| 2026-03-31 est. | P3 | Addpharma Inc. | NCT05400317 A Study to Evaluate the Efficacy and Safety of AD-218 | Mixed Dyslipidemia | recruiting | 520 |
| 2026-03-31 est. | P2 | Ever Neuro Pharma GmbH | NCT05755997 CERebrolysin In CADASIL | Cadasil | active not recruiting | 30 |
| 2026-03-31 | P2 | Biotheus Inc. | NCT05918107 A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM | MPM | completed | 31 |
| 2026-03-31 est. | P2 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06189495 A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab | Systemic Sclerosis Associated Interstitial Lung Disease; Rheumatoid Arthritis Associated Interstitia | recruiting | 30 |
| 2026-03-31 est. | P1/P2 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | NCT06223646 A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | unknown | 29 |
| 2026-03-31 est. | P1/P2 | Delta-Fly Pharma, Inc. | NCT06382168 DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | Leukemia, Myeloid, Acute | unknown | 39 |
| 2026-03-31 est. | P1/P2 | Chengdu Origen Biotechnology Co., Ltd. | NCT06458595 Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) | Age-related Macular Degeneration | recruiting | 44 |
| 2026-03-31 est. | P3 | Green Cross Wellbeing | NCT06493799 In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the E | Chronic Liver Disease | recruiting | 226 |
| 2026-03-31 est. | P3 | Chong Kun Dang Pharmaceutical | NCT06643819 Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A | Essential Hypertension | recruiting | 324 |
| 2026-03-31 | P2 | Sanofi SNY | NCT06691113 A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nas | Chronic Rhinosinusitis Without Nasal Polyps | completed | 66 |
| 2026-03-31 | P1/P2 | GuangZhou Cellgenes Biotechnology Co., Ltd. | NCT06740149 Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients | Acute-On-Chronic Liver Failure | completed | 100 |
| 2026-03-31 est. | P1/P2 | Shanghai Escugen Biotechnology Co., Ltd | NCT06853444 A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia | Immune Thrombocytopenia (ITP) | recruiting | 84 |
| 2026-03-31 est. | P3 | Ahn-Gook Pharmaceuticals Co.,Ltd | NCT07198347 Efficacy and Safety of AG2001 in Patients With Acute Bronchitis | Acute Bronchitis | not yet recruiting | 300 |
| 2026-03-31 est. | P3 | Longbio Pharma | NCT07291284 Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | active not recruiting | 546 |
| 2026-03-31 est. | P3 | NTC srl | NCT07465705 Clinical Trial on Bowel Preparation Comparing Mannitol 100g to Plenvu Both in a Same Day Regimen (CLEARWAY) | Elective Colonoscopy | recruiting | 412 |
| 2026-03-31 | P2 | Samsung Bioepis Co., Ltd. | NCT07550504 A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV | Age-Related Macular Degeneration; Branch Retinal Vein Occlusion With Macular Edema; Central Retinal | completed | 30 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.